TFG-MET/BAF3
CBP73391
| I. Introduction | |
| Cell Line Name： | TFG-MET/BAF3 |
| Host Cell: | Ba/F3 |
| Stability: | 16 passages (in-house test, that not means the cell line will be instable beyond the passages we tested.) |
| Application: | Anti-proliferation assay and PD assay |
| Freeze Medium: | 90% FBS+10% DMSO |
| Complete Culture Medium: | RPMI-1640+10%FBS+2ug/ml puromycin |
| Mycoplasma Status: | Negative |
| II. Background | |
|
TFG, trafficking from ER to golgi regulator, plays a role in regulation of intracellular trafficking and plays a role in the COPII-coated vesicle transport system. TFG fusions, with multiple gene partners, have been identified in several tumor types, including TFG-MET in thyroid carcinoma, TFG-RET in papillary thyroid cancer, TFG-FGFR1 in AML, and TFG-NR4A3 in extraskeletal myxoid chondrosarcoma. MET, MET proto-oncogene, receptor tyrosine kinase, is a receptor tyrosine kinase, which activates MAPK, PI3K/AKT, SRC, and STAT pathways to promote cell proliferation, invasion, and angiogenesis. MET mutations, exon 14 skipping mutations, and fusions have been identified in a variety of human cancers, including lung cancer, and MET amplification and/or overexpression has been reported in many solid tumors, including biliary tract cancer, breast cancer, NSCLC, gastric cancer, intrahepatic cholangiocarcinoma, and gallbladder carcinoma. |
|
| III. Representative Data | |
|
1. Anti-proliferation assay |
|
